Each MG patient was matched by year of birth, sex and practice to up to six patients without a history of MG to generate a matched cohort. The index date of MG diagnosis was the date of the first record of MG after GPRD data collection had started. Each control patient was assigned
the same index date as his matched MG patient. The study patients were followed up from this index date to either the end of GPRD data collection, the date of transfer of the patient out of the practice area, the patient’s death or the occurrence of fracture, whichever came first. All types of fracture were included in the analyses and classified according to the International Classification of Diseases, Tenth Revision (ICD-10) categories (HES) and corresponding read codes (GPRD). A typical osteoporotic fracture was defined as a fracture of the radius/ulna, humerus, rib, femur/hip, pelvis or vertebrae (clinically symptomatic). Subsequently, #Selleck Belinostat randurls[1|1|,|CHEM1|]# this population was then divided into a group of probable MG cases (n = 834) with their matched controls and a group of possible MG cases (n = 232) with their matches controls. The following criteria were used to determine a probable MG case: a recording of MG in two different registries (GPRD and HES) (n = 205), or it has a recording of MG in at least one
registry with either a letter from a neurologist confirming the patient has seen a neurologist ever before or 1 year after the diagnostic code (n = 291), or a record of thymectomy (n = 48) any time during follow-up (recorded either
in GPRD or HES) or at least two prescriptions on different days of pyridostigmine, oral Epigenetics Compound Library high throughput glucocorticoids, azathioprine, methotrexate, ciclosporin or mycophenolate mofetil any time during enrolment (n = 754). Possible cases Resminostat were identified if they had a recording of MG in either GPRD or HES without the abovementioned prescription data, recording of thymectomy or a letter from a neurologist. Patients were excluded if they had a record of Lambert–Eaton type myasthenic syndrome, which mimics MG. Exposure The indicators of MG severity selected for the study were selected from the myasthenia gravis Foundation of America postintervention status that were also recorded in the GPRD . Grade 1 included patients who did not use cholinesterase inhibitors or immunosuppressants during the past 6 months. Grade 2 included patients who used immunosuppressants, but not cholinesterase inhibitors during the past 6 months. Grade 3 included patients who used pyridostigmine only during the past 6 months (and no immunosupressants), and grade 4 included patients who had been on both immunosuppressants and cholinesterase inhibitors. MG severity grade may fluctuate over time. Potential confounders that were determined at baseline included body mass index (BMI), smoking status, alcohol status and occurrence of prior fractures.